Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$49.86 USD
+1.93 (4.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Earnings News For APLS
-
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
-
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?
-
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?
-
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
-
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?
-
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for
-
Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?
-
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates